Junshi Biosciences receives approval of toripalimab NDA from NMPA for first-line treatment of HER2 expressing urothelial carcinoma: Shanghai Saturday, May 23, 2026, 17:00 Hrs [IST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results